Stirling, Scotland - eClinicalHealth Limited, a technology and consulting company dedicated to providing innovative clinical trial solutions, has released a methodology to validate and standardize patient questionnaires across different data capture tools. With scientific support from ICON eCOA practice, eClinicalHealth’s methodology enables clinical trial participants to use their own electronic devices to record patient-reported outcomes while making it easier for researchers to ensure those devices are validated. Currently, to ensure ePRO tools used in studies meet U.S. FDA guidelines, sponsors often provide patients with dedicated devices - which can be costly, complex to manage and inconvenient. As an alternative, sponsors may ask patients to provide their own devices, requiring the sponsor to validate each instrument used - a task nearly impossible for most studies. To address this, eClinicalHealth developed a different approach, where a “migration standard” is developed for each instrument. Through collaboration with device makers and patient observation, key elements - such as minimum screen size and placement of instructions - are identified that the standard must address to ensure data captured electronically is of equivalent or better quality than the original paper design. The final, device-independent standard undergoes testing using the industry’s standard testing practices. With ICON eCOA practice, eClinicalHealth successfully developed a standard for the Anti-Clot Treatment Scale, which was subsequently deployed into clinical studies involving thousands of participants, allowing them to use their own computers, tablets and smartphones. “We’re pleased how well our methodology has worked in practice,” said Kai Langel, eClinicalHealth’s director of patient solutions. “This is an important step in making clinical research more practical without compromising data quality.” “Our collaboration with eClinicalHealth proves that new concepts to validate instruments can be developed to support successful bring-your-own-device models,” said Willie Muehlhausen, ICON’s head of innovation. eClinicalHealth presented a poster about this methodology at the ISPOR annual meeting in May and will present an eCH/ICON-sponsored webinar July 28 at 9 a.m. ET/14:00 UK. For more information, visit www.clinpal.com or www.iconplc.com. About eClinicalHealth Limited Headquartered in Scotland, eClinicalHealth Limited, developers of the revolutionary Clinpal patient engagement platform, was founded in early 2012 to provide innovative clinical trial solutions. The company is committed to leading open and collaborative innovation discussions about remote clinical trial processes and technology with pharmaceutical companies, CROs and other service and technology providers.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.